Amarin Corporation PLC
NASDAQ:AMRN
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IE |
|
Amarin Corporation PLC
NASDAQ:AMRN
|
310.9m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.3B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
65.1B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
36.5B EUR |
Loading...
|
Market Distribution
| Min | -37.7% |
| 30th Percentile | 19.3% |
| Median | 32% |
| 70th Percentile | 38.1% |
| Max | 1 012% |
Other Profitability Ratios
Amarin Corporation PLC
Glance View
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics for cardiovascular disease management. The firm operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Amarin Corporation PLC is 56.6%, which is below its 3-year median of 60.5%.
Over the last 3 years, Amarin Corporation PLC’s Gross Margin has decreased from 70.6% to 56.6%. During this period, it reached a low of 51.6% on Dec 31, 2024 and a high of 71.2% on Jun 30, 2023.
